Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.66 |
| ▸ | POLB | P06746 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6999632 | 0.82 | RAB9A (0.62) | HPGDALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL31701605 | 0.80 | MAPT (0.66) | HPGDPOLBALDH1A1KDM4ELMNA | |
| SCHEMBL17988255 | 0.79 | ALDH1A1 (0.68) | HPGDPOLBALDH1A1KDM4ELMNA | |
| SCHEMBL9733822 | 0.76 | ALDH1A1 (0.60) | HPGDPOLBALDH1A1KDM4ELMNA | |
| SCHEMBL6266730 | 0.76 | POLB (0.56) | HPGDPOLBALDH1A1KDM4ELMNA | |
| SCHEMBL31701624 | 0.76 | ALDH1A1 (0.64) | HPGDPOLBALDH1A1KDM4ELMNA | |
| SCHEMBL31701007 | 0.74 | ALDH1A1 (0.62) | HPGDPOLBALDH1A1KDM4ELMNA | |
| SCHEMBL4956714 | 0.74 | HPGD (0.53) | HPGDPOLBALDH1A1KDM4ELMNA | |
| SCHEMBL31702048 | 0.74 | ALDH1A1 (0.56) | HPGDPOLBALDH1A1KDM4ELMNA | |
| SCHEMBL7673789 | 0.72 | ALDH1A1 (0.62) | HPGDALDH1A1KDM4ELMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128972-A1 | Anat Inhibitors and Methods of Use Thereof | Atomwise Inc. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128972-A1 | Anat Inhibitors and Methods of Use Thereof | AANAT, CHAT, NAT1 | HPGD 637/4885POLB 1726/4885ALDH1A1 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.